Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluatin

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent

marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Canada , United States , Gursel Aktan , Twitter , Data Monitoring Committee , Drug Administration , Statement Of Merck Co Inc , Instagram , Youtube , European Network For Gynecologic Oncology Trial , Facebook , Merck Research Laboratories , Foundation Inc , Exchange Commission , Merck Co Inc , Linkedin , Merck Research , Biologics License Application , Prescription Drug User Fee Act , European Network , Gynecologic Oncology Trial , Among Merck , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse Reactions , Single Agent , Thyroid Disorders , Which Can Present With Diabetic Ketoacidosis , Nervous System , Connective Tissue , Patients With Multiple Myeloma , Neck Squamous Cell Cancer , Bacillus Calmette Guerin , Mismatch Repair Deficient Cancer , Mismatch Repair Deficient Colorectal Cancer , Prescribing Information , Medication Guide , Safety Information , Posterior Leukoencephalopathy Syndrome , Thyroid Stimulating Hormone , Specific Populations , Looking Statement , Securities Litigation Reform Act , Annual Report ,